Drug developers have long needed to diversify clinical trials to improve the safety, efficacy, and adoption of new therapies among historically underrepresented groups. “This isn’t new for us,” says Giovanni Caforio, CEO of Bristol Myers Squibb, which makes treatments for everything from cancer to HIV/AIDS. But BMS made big strides this year. Now, 58% of its U.S. trial sites (compared with a 25% goal) are located in communities that have at least a 30% nonwhite population. It also increased nonwhite-patient recruitment by 22%. There’s more work to be done, but BMS’s sustained focus on diversity is yielding real progress.
More from TIME
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
- Cybersecurity Experts Are Sounding the Alarm on DOGE
- Meet the 2025 Women of the Year
- The Harsh Truth About Disability Inclusion
- Why Do More Young Adults Have Cancer?
- Colman Domingo Leads With Radical Love
- How to Get Better at Doing Things Alone
- Michelle Zauner Stares Down the Darkness
